Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus by Pariente, Nonia et al.
JOURNAL OF VIROLOGY, June 2003, p. 7131–7138 Vol. 77, No. 12
0022-538X/03/$08.000 DOI: 10.1128/JVI.77.12.7131–7138.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Mutagenesis versus Inhibition in the Efficiency of Extinction of
Foot-and-Mouth Disease Virus
Nonia Pariente, Antero Airaksinen, and Esteban Domingo*
Centro de Biología Molecular Severo Ochoa, Universidad Auto´noma de Madrid,
Cantoblanco, 28049 Madrid, Spain
Received 20 December 2002/Accepted 21 March 2003
RNA viruses replicate near the error threshold for maintenance of genetic information, and an increase in
mutation frequency during replication may drive RNA viruses to extinction in a process termed lethal
mutagenesis. This report addresses the efficiency of extinction (versus escape from extinction) of foot-and-
mouth disease virus (FMDV) by combinations of the mutagenic base analog 5-fluorouracil (FU) and the
antiviral inhibitors guanidine hydrochloride (G) and heparin (H). Selection of G- or H-resistant, extinction-
escape mutants occurred with low-fitness virus only in the absence of FU and with high-fitness virus with some
mutagen-inhibitor combinations tested. The combination of FU, G, and H prevented selection of extinction-
escape mutants in all cases examined, and extinction of high-fitness FMDV could not be achieved by equivalent
inhibitory activity exerted by the nonmutagenic agents. The G-resistant phenotype was mapped in nonstruc-
tural protein 2C by introducing the relevant mutations in infectious cDNA clones. Decreases in FMDV
infectivity were accompanied by modest decreases in the intracellular and extracellular levels of FMDV RNA,
maximal intracellular concentrations of FU triphosphate, and a decrease in the intracellular concentrations of
UTP. In addition to indicating a key participation of mutagenesis in virus extinction, the results suggest that
picornaviruses provide versatile experimental systems to approach the problem of extinction failure associated
with inhibitor-escape mutants during treatments based on enhanced mutagenesis.
The error rate during template copying by viral RNA-de-
pendent RNA polymerases and reverse transcriptases is close
to the maximum tolerable for the maintenance of the genetic
information of the virus. This is supported by theoretical pre-
dictions (reviewed in references 14 and 15) and experimental
results on the adverse effects of enhanced mutagenesis on
infectivity during cytolytic or persistent infections of viruses as
diverse as picornaviruses (1, 9, 10, 23, 35, 52), retroviruses and
retroviral vectors (29, 30, 37), the rhabdovirus vesicular stoma-
titis virus (VSV) (23), the flavivirus GB virus B (27), the arena-
virus lymphocytic choriomeningitis virus (LCMV) (21, 46), and
Hantaan virus (50).
Virus extinction by enhanced mutagenesis was accompanied
by increases in mutant spectrum complexity, as quantitated by
mutation frequency and Shannon entropy (1, 21, 35, 46, 52).
LCMV showed a very high sensitivity to extinction by 5-flu-
orouracil (FU) during persistent infections in BHK-21 cells
(21, 46), and recently it has been shown that administration of
FU to mice prevented the establishment of a persistent LCMV
infection (46), providing the first evidence of feasibility of a
lethal mutagenesis approach to control viral infections in vivo.
Studies with the important animal pathogen foot-and-mouth
disease virus (FMDV) have documented that low viral relative
fitness and low viral load favored FMDV extinction by en-
hanced mutagenesis (35, 52). The effect of fitness was evi-
denced using FMDV clones which differed up to 106-fold in
relative fitness values. In particular, FMDV MARLS (a mono-
clonal antibody [MAb]-escape mutant of FMDV clone C-S8c1
passaged 213 times in BHK-21 cells [7]) displays high fitness in
BHK-21 cells and low fitness in Chinese hamster ovary (CHO)
cells. In CHO cells, three serial passages in the presence of FU
were sufficient to extinguish FMDV MARLS, while in BHK-21
cells, a combination of FU and the antiviral inhibitors guani-
dine hydrochloride (G) and heparin (H) was necessary to ex-
tinguish FMDV MARLS (35).
Treatment of FMDV of different relative fitness values with
FU with or without the inhibitors G and H offered the possi-
bility of studying the effect of viral fitness on the competing
forces exerted by the mutagenic action of FU towards viral
extinction and the tendency to select G- or H-escape mutants
of FMDV that would result in an increase in viral load and
avoidance of virus extinction. The results presented here doc-
ument an advantage of mutagenic versus purely inhibitory
treatments with regard to loss of infectivity and point to rela-
tive fitness as a key parameter to permit survival of inhibitor-
escape mutants.
Effect of FU treatment on intracellular nucleotide pools and
FUTP accumulation in BHK-21 cells. The mutagenic effect of
FU in RNA viruses (6, 13, 19, 21–23, 35, 42, 46, 52, 57) is the
result of incorporation of FU triphosphate (FUTP) into RNA
(8, 20, 28, 36, 58). The mutagenic pathway involves the pref-
erential incorporation of FUTP opposite to A and the ensuing
misincorporation of G instead of A at the complementary
position, presumably because pairing of G with FU in the
template RNA is favored (59). This mechanism would result in
the generation of transitions A3G and U3C, which are the
most frequent mutation types induced by FU in two experi-
mental models, FMDV and LCMV (21, 35, 46, 52). To deter-
mine the intracellular concentrations of FUTP, UTP, ATP,
CTP, and GTP, extracts of BHK-21 cells were obtained at
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different times of exposure to 50, 100, or 200 g of FU/ml in
the culture medium and subjected to high-performance liquid
chromatography (HPLC) analysis as previously described (1,
41). The peaks of ATP, ADP, CTP, GTP, UTP, and FUTP
were identified by comparing the observed retention times with
those obtained with commercial nucleotide solutions. The
peak of FUTP was the only additional peak in the nucleoside
triphosphate (NTP) zone of the chromatograms (together with
those of ATP, CTP, GTP, and UTP) that appeared in FU-
treated samples, and its retention time was the same as that of
commercial FUTP (Sierra Research). The ATP:ADP ratio was
always above 20, indicating minimal loss of the terminal phos-
phate during sample preparation. Intracellular FUTP concen-
trations increased during the first 17 h of treatment with FU
and decreased modestly after 18 h of exposure, reaching levels
similar to those present after 10 h of treatment. These levels
were maintained until at least 38 h of exposure to FU (Fig.
1A). Under our standard conditions of treatment with FU
during FMDV infections (preincubation of cells with FU for
13 h followed by infection with FMDV for 24 h in the presence
of FU [35, 52]), the intracellular FUTP content is between 23
and 30 fmol/cell (Fig. 1A). The relative concentrations of in-
tracellular UTP, CTP, ATP, and GTP following exposure to
50, 100, or 200 g of FU/ml were compared with those of
parallel, untreated cultures (Fig. 1B). The most pronounced
effect of FU treatment was a decrease of the intracellular
concentration of UTP in a dose-dependent manner. After 10 h
of exposure, 200 g of FU/ml produced a 2.5-fold reduction in
UTP levels, with respect to the control, and a 4.2-fold reduc-
tion after 24 h that was maintained until at least 38 h postex-
posure to FU. There was approximately ten times more FUTP
than UTP in the cells during FMDV replication. There was a
slight increase in GTP levels, although not in a FU dose-
dependent manner, and there was no discernible effect on CTP
and ATP levels (Fig. 1B). The same results were obtained
when nucleotides were extracted from cultures treated for 4, 7,
10, and 24 h with FU (200 g/ml)  G (4 mM) (after prein-
cubation with FU for 13 h) (data not shown). We conclude that
the maximum effects on nucleotide pools resulting from FU
treatment occur during the period of FMDV infection under
our experimental conditions (35, 52).
An essential contribution of mutagenesis versus inhibition
in the extinction of FMDV. To investigate a possible advantage
of using a mutagen, as opposed to using only antiviral inhibi-
tors, to drive FMDV to extinction, we treated FMDVs differ-
ing up to 150-fold in relative fitness with different combinations
of drugs. The mutagen and antiviral inhibitors used, as well as
the procedures used to infect BHK-21 cells in liquid medium
FIG. 1. FUTP accumulation and changes in intracellular ribonucleotide concentrations in FU-treated BHK-21 cells. (A) Intracellular FUTP
concentrations were determined from BHK-21 cell cultures treated with FU (50 g/ml) (dashed black lines with black circles), FU (100 g/ml)
(dashed black lines with black diamonds) and FU (200 g/ml) (black lines with white squares). Assuming a cell volume of 3.6 ml/109 cells (55),
the maximal intracellular FUTP concentration was approximately 7.5 mM. (B) Intracellular NTP concentrations were determined from BHK-21
cell cultures treated with Dulbecco’s modified Eagle medium (DMEM) (solid lines with black squares), FU (50 g/ml) (dashed gray lines with
white circles), FU (100 g/ml) (dashed gray lines with gray diamonds), and FU (200 g/ml) (black lines with white squares). Note that the scale
shown in ordinate is different in each graph. In all cases, samples were prepared for HPLC analysis at 4, 7, 10, and 13 h of exposure. After 13 h,
the plates were mock infected (medium was removed and 200 l of DMEM was added to mimic a real infection), and after 1 h, fresh medium
with FU was added. NTPs were again extracted at 18, 21, 24, and 38 h (4, 7, 10, and 24 h after fresh medium was added).
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and for plaque assays, have been previously described (5, 12,
35). The concentrations of FU, G, and H (expressed in micro-
grams per milliliter for FU, milligrams per milliliter for H, and
millimolar for G, to facilitate comparison of results of other
laboratories) are indicated in parentheses following the corre-
sponding abbreviation. Combination treatments are indicated
with a “” between the drugs employed in the treatment. The
cytotoxicity of treatments with FU (200 g/ml); G (4 mM);
H (1 mg/ml); FU (200 g/ml)  G (4 mM); FU (200 g/ml) 
G (4 mM)  H (1 mg/ml); and G (4 mM)  H (1 mg/ml) has
been previously described (35). The rest of treatments used in
this report were only cytostatic, except G (8 mM)  H (1 mg/
ml), which was cytotoxic (85% viable cells after 38 h of treat-
ment). For all three FMDVs analyzed, namely, H95
5 , REDpt60,
and MARLS, when only one drug was used, either FU or an
antiviral inhibitor, viral suppression was greater in the pres-
ence of FU and led to extinction of H95
5 and REDpt60 but not
of MARLS (Fig. 2A, C, and E). Most of the combination
treatments used had a similar antiviral effect in one passage
(the reduction in viral titer was equivalent) whether they in-
cluded FU or only combinations of the inhibitors G and H
(Fig. 2B, D, and F).
FMDV H95
5 is a virus obtained after two passages of a mix-
ture of five biological clones that were isolated after 95 plaque-
to-plaque transfers of clone H5 (derived from C-S8c1p113
[16]) (18, 35); it has a relative fitness value of 0.05 with respect
to our reference clone C-S8c1 (53). Combinations G (3 mM)
H (0.5 mg/ml) and G (3 mM)  H (1 mg/ml), which inhibited
H95
5 production as much as FU (100 g/ml), led to virus ex-
tinction in three passages, like two out of four series of pas-
sages in the presence of FU (100 g/ml) (Fig. 2B). Combina-
tion G (2 mM)  H (1 mg/ml), which inhibited almost as much
as the other combinations, failed to extinguish the virus, and
mutants of H95
5 that are resistant to H emerged (Table 1). Since
H95
5 in the presence of FU (200 g/ml) became undetectable in
one passage and the virus was extinguished in two passages, a
lower concentration of FU (100 g/ml) was used to compare
with combination treatments without mutagen (in order to
obtain comparable inhibitions with and without mutagen).
The origin of FMDV REDpt60 has been previously de-
FIG. 2. Production of infectious virus upon passage of FMDVs H95
5 (A and B), REDpt60 (C and D), and MARLS (E and F) in the presence
of different drug combinations in BHK-21 cells. Conditions for mutagenic and antiviral treatments have been previously described (35). In all cases,
virus was tested by infecting 9  105 BHK-21 cells with 5 104 PFU of virus, and the next passages were carried out by infecting cells with 0.1 ml
of supernatant from the previous passage. The multiplicity of infection can be calculated from the titers shown in ordinate. The legend panels
identify drug treatments of the assays shown on their left. DMEM indicates culture medium in the absence of mutagen and inhibitor. Passages one
to four depicted in panel E were published previously (35), and are included here for completeness. Preextinction populations are indicated by
arrows. Viral extinction was ascertained by three additional blind passages in the absence of mutagen and inhibitors, with no evidence of infectivity
or RT-PCR-amplifiable material in the supernatant of the third passage (35, 52). All titrations were done in triplicate. Standard deviations (not
included in the plots) never exceeded 20%.
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scribed (45). This virus has a relative fitness 1.5 times higher
than that of C-S8c1. Treatment of REDpt60 with FU (200
g/ml)  H (1 mg/ml) and with G (5 mM)  H (1 mg/ml)
exerted the same antiviral effect in one passage, and treatments
with FU (200 g/ml)  G (4 mM) with or without H (1 mg/ml)
exerted a higher antiviral effect, but all these treatments extin-
guished the virus (Fig. 2D). REDpt60 treated with G (5 mM)
 H (1 mg/ml) was extinguished in two passages, and extinc-
tion with FU (200 g/ml)  G (4 mM), FU (200 g/ml)  H
(1 mg/ml), and FU (200 g/ml)  G (4 mM)  H (1 mg/ml)
was attained in three passages. However, with FU (200 g/ml)
G (4 mM) with and without H (1 mg/ml), no infectivity could
be detected in a plaque assay in one passage (but virus was
recovered in the second blind passage). It was unexpected that
REDpt60 could be extinguished with FU (200 g/ml) alone
while C-S8c1, of comparable fitness, could not (35, 52). This
difference may relate to mutations present in REDpt60 that,
although not impairing fitness under standard culture condi-
tions, may render this genome less tolerant to environmental
perturbations, as previously described for VSV (43).
In the case of MARLS (5, 31, 33), a clone with a relative
fitness 130-fold higher than that of C-S8c1, only treatments in
which FU was present in combination with inhibitors were
successful in driving the virus to extinction (Fig. 2F), even
though a similar antiviral effect was exerted by the combination
treatment G (8 mM)  H (1 mg/ml). One of the duplicates
passaged in the presence of FU (200 g/ml)  H (1 mg/ml),
which exerted 1 logarithm less antiviral effect in one passage,
was also extinguished. These results document an essential
contribution of mutagenesis versus inhibition in driving FMDV
populations to extinction.
Characterization of escape mutants to treatments with FU,
G, and/or H. When extinction of H95
5 , REDpt60, or MARLS
was not accomplished during the passages in the presence of
different antiviral treatments (Fig. 2), viral RNA was extracted
from the supernatant of the fifth passage, amplified by reverse
transcription-PCR (RT-PCR), and sequenced to investigate
the possible presence of drug resistance mutations. The non-
structural protein 2C was analyzed when the treatment con-
tained G, because resistance to G has previously been found to
map to this protein (3, 38–40, 48, 49). The entire capsid-coding
region was analyzed when H was included in the treatment,
because amino acids that affect binding to H are located in the
capsid (4, 5, 24, 44, 47). Mutations conferring resistance to H
have been studied (4, 44) and map to capsid amino acid posi-
tions usually representing a loss of a positive charge or, less
frequently, the addition of a positive charge in the vicinity of an
already existing one. Whenever FMDVs were not extin-
guished, viruses with mutations that confer resistance to G or
H were selected (Table 1). Some other mutations appeared in
VP3 and VP1, either in a dominant form or in a mixture with
the wild-type amino acid, that do not confer a change in
charge. Their possible contribution to H resistance has not
been described (Table 1). All the changes, whether or not they
TABLE 1. Substitutions found in FMDVs H95
5 , REDpt60, and MARLS subjected to treatments that did not lead to viral extinction
Viral population and
treatmenta
Substitutions
in 2Cb
Substitutions in the capsidb:
VP3 VP1
H95
5
G (4 mM)p5A M1593L ND ND
G (4 mM)p5B M1593L ND ND
H (1 mg/ml)p5A ND K1733T —
H (1 mg/ml)p5B ND K1733T —
G (2 mM) Hp5A — K1733E —
G (2 mM) Hp5B — K1733K/E —
REDpt60
G (4 mM)p5A M1593M/L ND ND
G (4 mM)p5B M1593L ND ND
H (1 mg/ml)p5A ND — R1333Q
H (1 mg/ml)p5B ND — R1333Q
MARLS
G (4 mM)p5A M1593M/L ND ND
G (4 mM)p5B C1413C/S ND ND
H (1 mg/ml)p5A ND T673T/I, D683D/H K2063K/I, D523D/A
H (1 mg/ml)p5B ND D683D/H —
G (4 mM) H (1 mg/ml)p5A K1693R T673T/I, D683D/H N603T
G (4 mM) H (1 mg/ml)p5B C1413S K1733E S1443L
FU (200 g/ml) G (4 mM)p5A M1593L ND ND
FU (200 g/ml) G (4 mM)p5B M1593L ND ND
FU (200 g/ml) H (1 mg/ml)p5B ND K2183K/E K2063Q
G (8 mM) H (1 mg/ml)p5A K1693R — —
G (8 mM) H (1 mg/ml)p5B M1593L M1283T —
a The viral populations analyzed and the antiviral treatments used are described in the text. The viral populations analyzed are those described in Fig. 3; p indicates
the passage number, and A and B distinguish duplicate series.
b The single-letter amino acid code is used. Amino acids are numbered independently for each protein (16, 17). When the antiviral treatment used contained G, the
2C protein was sequenced; when H was used, the capsid-coding region of the virus was sequenced; when both G and H were used, both regions of the genome were
sequenced. Mixtures are indicated with the two amino acids separated with a slash. Substitutions are determined in each case by comparison with the consensus
sequence of the corresponding parental virus. No amino acid substitutions were found in VP4 and VP2. —, absence of substitution; ND, not determined.
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involved a change of charge, appeared in exposed positions of
the capsid (32). All preextinction populations had the wild-type
sequence, indicating lack of selection of resistance mutations,
a fact that presumably was determinantal for the extinction
observed.
Early work showed that G resistance mutations in FMDV
map to protein 2C (48, 49), as in the case of poliovirus (2, 3, 39,
40), and a specific mutation in the carboxy-terminal part of 2C
of FMDV O6 was defined (49). We introduced the mutations
that we found among FMDV clones and populations passaged
in the presence of G in a chimeric infectious clone (references
34 and 60 and references therein) to determine whether the
mutations conferred the G resistance phenotype (Fig. 3). Mu-
tations leading to K169R and I248T were introduced, either
individually or together, in the C-S8c1 background, and muta-
tions C141S and M159L were introduced in the MARLS se-
quence context. Positions 169 and 248 of 2C were substituted
frequently in C-S8c1 passaged in the presence of G and were
found together in several G-resistant biological clones (results
not shown). When introduced separately in an infectious clone,
the second mutation arose promptly after transfection, indi-
cating a selective advantage of a virus harboring the two re-
placements, even in the absence of G. Substitutions in posi-
tions 141 or 159 were found always in the context of multiply
passaged FMDVs (never in the C-S8c1) and always as the only
change present in 2C, never in combination, and thus we in-
troduced these changes in the sequence context of MARLS 2C
(which presents four amino acid changes with respect to
C-S8c1 [Fig. 3]). The G resistance phenotype was character-
ized with a plaque assay in the presence or absence of G (the
results for viruses with mutations K169R and I248T are shown
in Fig. 4A). C-S8c1 and the wild-type chimera showed a re-
duction of 2.5 logarithms of viral production in the presence of
4 mM G, whereas the mutated chimeras showed no difference
in viral production in the presence of 4 mM G. Substitution
C141S conferred a resistant phenotype, with similar viral pro-
duction in the presence or absence of G. The virus with M159L
was partially resistant, and with 8 mM G, the viral produc-
tion was somewhat less than 2 logarithms higher than for
C/MARLS, although it was 1 logarithm lower than in the
absence of G (Fig. 4B).
Viral RNA levels during C-S8c1 infection in the presence of
FU (200 g/ml) with and without G (4 mM). The amount of
viral RNA during the replication of C-S8c1 in the presence of
FU (200 g/ml) with and without G (4 mM) was compared
with that of a parallel infection in the absence of FU and G
(Fig. 5). The presence of G led to a 1-logarithm decrease in
viral production and in the intracellular and extracellular RNA
levels. The reduction of intracellular and extracellular RNA
levels observed in the presence of FU accounts for only 1/10 of
the reduction of infectivity. From the data of Fig. 5, it can be
estimated that in the presence of FU (with or without G), the
ratio of infectivity to the amount of extracellular viral RNA at
24 h postinfection was 20-fold lower than in infections in the
absence of FU. We conclude that during FMDV infections, the
main force driving the virus to extinction is the mutagenic effect of
FU rather than the decrease in RNA levels during the infection.
Mutagenic action of FU and the problem of virus extinction
versus escape. FU inhibits the cellular enzyme TMP syn-
thetase, which catalyzes the conversion of dUMP into TMP.
Due to this activity, dTTP levels are significantly reduced,
dGTP and dCTP levels are moderately reduced, and dATP
levels are unaltered (20, 26, 36), but to our knowledge, no
quantitations of the effect of FU on NTP pools have been
reported. We have used this mutagen to drive FMDV into
extinction (35, 52) and investigated whether the NTP levels in
FIG. 3. FMDV chimeric plasmids. The scheme on the top of the figure represents FMDV C-S8c1 genomic regions encoding proteins VP4 to
3D. Numbering of FMDV genomic nucleotides is according to Toja et al. (54). Relevant restriction sites used for construction of chimeric cDNAs
are indicated at the top, with the 5 position of the restriction site given in parentheses. Below the FMDV C-S8c1 genome scheme are the different
chimeric plasmids used in this study. In plasmid pC (34), the C-S8c1 FMDV region spans residues 1739 to 7427, which correspond to protein
residues S33 of VP4 to W283 of 3D. The rest of the FMDV genome is that of FMDV O1K (serotype O) (shaded boxes) (60). Bold residues in
the 2C box are those introduced to study their implication in resistance to G. The position numbers of amino acids in 2C that differ between C-S8c1
and MARLS and the positions on the 2C protein altered by site-directed mutagenesis are indicated at the bottom.
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BHK-21 cells were altered during this process. Mutagenesis
might be mediated by the alteration in NTP pools, direct in-
corporation of FU into nascent viral RNA and the subsequent
mispairing with G, or both. The results indicate that UTP is
depleted in BHK-21 cells treated with FU but that the other
NTPs remain at close-to-normal levels. In our system, FU
accumulates in BHK-21 cells and is converted into FUTP,
resulting in an FUTP concentration ten times higher than that
of UTP in BHK-21 cells during replication of FMDV. This
result suggests that the probable mechanism for FU-induced
mutagenesis is direct incorporation into RNA, because it seems
unlikely that the small alterations in NTP pools observed are
responsible for the degree of mutagenesis induced by FU on
FMDV (35, 52). Further studies with FMDV polymerase in
vitro would be necessary to prove the incorporation of FUTP.
FU caused a 100-fold inhibition of C-S8c1 infectivity and a
10-fold reduction of the amount of viral RNA. This observa-
tion suggests that most of the RNA may be noninfectious due
to accumulation of mutations, which we have reported previ-
ously using the same system (35, 52). These results are in
agreement with the results showing that a 100-fold reduction of
LCMV infectivity induced with FU treatment was associated
with a 5-fold reduction in RNA synthesis (46). This provides
further support to the evidence that, although FU can have
other effects on cellular RNA species (20, 28, 36, 58) and on
virus replication (19), mutagenesis is a major factor operating
during FMDV and LCMV extinction (14, 21, 35, 46, 51, 52).
The efficient extinction of FMDV with combinations of FU
and inhibitors has been previously described (35). Here we
have documented that there is an advantage in the use of a
mutagen over treatments without mutagen that achieve a sim-
ilar degree of inhibition in relation to the selection of inhibitor-
escape mutants. We have shown that for high-fitness FMDV,
extinction is achieved only when a mutagen is present in the
treatment. In the absence of FU, inhibitor-escape mutants
were selected. However, intermediate- and low-fitness FMDVs
could be extinguished with combination treatments without
FU in the same or even a lower number of passages. REDpt60
is an intermediate-fitness FMDV population obtained after 60
plaque-to-plaque transfers (45). The accumulation of muta-
tions associated with serial plaque-to-plaque transfers of
FMDV (16, 18) may have rendered REDpt60 more susceptible
to extinction than other viruses, such as C-S8c1, of equivalent
relative fitness in BHK-21 cells (references 18 and 45 and data
not shown). REDpt60 could be extinguished with FU in four
passages under the same conditions in which C-S8c1 was not
extinguished (52). The phenomenon underlying the sensitivity
to extinction of REDpt60 could be contingent neutrality of
accumulated mutations, first described with a VSV mutant
that, despite showing fitness equal to that of the wild type
under standard cell culture conditions, manifested a selective
disadvantage when a number of environmental perturbations
intervened during viral replication (43). Theoretical studies
have also suggested the advantage of replicons with increased
robustness against mutations (56). Other examples of extinc-
tion-prone combinations of mutations of viruses that show high
fitness in a specific environment have been reviewed (11).
We have identified four replacements in the 2C protein that
confer G resistance to FMDV serotype C, namely, C141S,
M159L, K169R, and I248T. The resistance to G has been
mapped in protein 2C for several picornaviruses, such as po-
liovirus (2, 3, 39, 40), echovirus-9 (25), and FMDV serotype O
(48, 49). The determinants for G resistance in FMDV serotype
C were not obvious, because one of the mutations that confer
high G-resistance to poliovirus is N1793G (39), and in FMDV
there is a G at this position. Introduction of the relevant
mutations into cDNA clones to produce the corresponding
infectious transcripts confirmed their association with the G
resistance phenotype.
FIG. 4. Viral production in the presence or absence of G. Black
columns represent viral production in the absence of G, empty col-
umns indicate viral production in the presence of 4 mM G, and gray
columns indicate viral production in the presence of 8 mM G. BHK-21
cells (2  106 to 4  106) were infected with serial dilutions of virus.
After 45 min of adsorption, cells were overlaid with 0.5% agar medium
with either 0, 4, or 8 mM G. After 24 h, cells were fixed with 2%
formaldehyde and visualized by crystal violet staining. Viral production
was estimated from the number of plaques and the viral dilution. The
amino acid substitutions present in 2C of each virus tested are shown
below the corresponding column. (A) Viruses derived from C-S8c1.
C-S8c1GR is a G-resistant population obtained after four passages in
the presence of 4 mM G. C is the virus obtained from chimera pC.
(B) Viruses derived from MARLS. MARLSGR is a G-resistant pop-
ulation obtained after four passages in the presence of 4 mM G. Vi-
ruses were plated with 8 mM G because MARLS is partially resistant
to G (there are four amino acid changes between the 2C of C-S8c1 and
MARLS, and the 50% inhibitory concentration for MARLS is 2.7
times higher than that of C-S8c1) and because the difference in plaque
formation was better assessed at higher concentrations of G. Sequence
differences in protein 2C between the chimeras used in this experiment
are depicted in Fig. 3.
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Virus entry into error catastrophe is a promising new anti-
viral strategy (9, 10, 11, 14, 21, 23, 27, 29, 30, 35, 37, 46, 50, 51,
52) strongly encouraged by the recent observation of Ruiz-
Jarabo et al. that FU treatment can prevent the establishment
of a persistent LCMV infection in mice (46). However, a prac-
tical application of this antiviral strategy will require the
finding of adequate, nontoxic, virus-specific mutagenic agents.
Since low viral loads and low relative fitness favor virus extinc-
tion by enhanced mutagenesis (35, 51, 52), it may be necessary
to design treatments to procure a low viral fitness at the onset
of the mutagenic treatment and/or a low viral load by employ-
ing antiviral inhibitors and mutagens in succession or in com-
bination. In these designs, it becomes critical to study the
dynamics of viral extinction versus selection of inhibitor-resis-
tant mutants that may mediate escape from extinction. The
present report on FMDV has illustrated the contribution of
mutagenesis to virus extinction, as well as escape of extinction
through selection of inhibitor-resistant mutants whenever the
intensities of the mutagenic and inhibitory activities were not
commensurate with the fitness of the virus to be extinguished.
The results presented here alert us to the need of a careful
design of experiments to test the potential of enhanced mu-
tagenesis in vivo and show that picornaviruses may provide
adequate experimental systems to explore critical parameters
before approaching more complex viral diseases.
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